Related references
Note: Only part of the references are listed.Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects
Nam-Tae Kim et al.
ARCHIVES OF PHARMACAL RESEARCH (2022)
Pharmacogenetics: A precision medicine approach to combatting the opioid epidemic
D. Max Smith et al.
JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY (2022)
Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients
Eui Hyun Jung et al.
ARCHIVES OF PHARMACAL RESEARCH (2021)
Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes
Chang-Keun Cho et al.
ARCHIVES OF PHARMACAL RESEARCH (2021)
Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele
Chang‑Keun Cho et al.
ARCHIVES OF PHARMACAL RESEARCH (2021)
Physiologically-Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective
Tycho Heimbach et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Physiologically Based Precision Dosing Approach for Drug-Drug-Gene Interactions: A Simvastatin Network Analysis
Jan-Georg Wojtyniak et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Physiologically based pharmacokinetic modeling of tramadol to inform dose adjustment and drug-drug interactions according to CYP2D6 phenotypes
Miao Xu et al.
PHARMACOTHERAPY (2021)
Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism
Young-Hoon Kim et al.
ARCHIVES OF PHARMACAL RESEARCH (2021)
Physiologically Based Pharmacokinetics Model in Pregnancy: A Regulatory Perspective on Model Evaluation
Paola Coppola et al.
FRONTIERS IN PEDIATRICS (2021)
A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions
Xia Li et al.
CLINICAL PHARMACOKINETICS (2020)
Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs
Katherine N. Theken et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Relationship between plasma exposure of zolpidem and CYP2D6 genotype in healthy Korean subjects
Eui Hyun Jung et al.
ARCHIVES OF PHARMACAL RESEARCH (2020)
Drug dosing during pregnancy-opportunities for physiologically based pharmacokinetic models
Khaled Abduljalil et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2020)
Physiologically-based pharmacokinetic models for children: Starting to reach maturation?
Laurens F. M. Verscheijden et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes
Eui Hyun Jung et al.
ARCHIVES OF PHARMACAL RESEARCH (2020)
Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions
Simeon Ruedesheim et al.
PHARMACEUTICS (2020)
Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide
Jung-Woo Bae et al.
ARCHIVES OF PHARMACAL RESEARCH (2020)
ABCB1 c.2677G>T/c.3435C>T diplotype increases the early-phase oral absorption of losartan
Hyo-Bin Shin et al.
ARCHIVES OF PHARMACAL RESEARCH (2020)
Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen
Ioannis Loisios-Konstantinidis et al.
PHARMACEUTICS (2020)
Data Digitizing: Accurate and Precise Data Extraction for Quantitative Systems Pharmacology and Physiologically-Based Pharmacokinetic Modeling
Jan-Georg Wojtyniak et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2020)
State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development
Venkata Yellepeddi et al.
CLINICAL PHARMACOKINETICS (2019)
Justification of Biowaiver and Dissolution Rate Specifications for Piroxicam Immediate Release Products Based on Physiologically Based Pharmacokinetic Modeling: An In-Depth Analysis
Xiaoting Li et al.
MOLECULAR PHARMACEUTICS (2019)
Influence of CYP2D6 genetic polymorphism on pharmacokinetics of active moiety of tolterodine
Ji-Yeong Byeon et al.
ARCHIVES OF PHARMACAL RESEARCH (2019)
Effects of steady-state clarithromycin on the pharmacokinetics of zolpidem in healthy subjects
Choong-Min Lee et al.
ARCHIVES OF PHARMACAL RESEARCH (2019)
Effects of diltiazem, a moderate inhibitor of CYP3A4, on the pharmacokinetics of tamsulosin in different CYP2D6 genotypes
Ji-Yeong Byeon et al.
ARCHIVES OF PHARMACAL RESEARCH (2018)
Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes
Se-Hyung Kim et al.
SCIENTIFIC REPORTS (2018)
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations
Ann K. Daly et al.
JOURNAL OF PERSONALIZED MEDICINE (2018)
Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite
Se-Hyung Kim et al.
ARCHIVES OF PHARMACAL RESEARCH (2017)
Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions
Weize Huang et al.
DRUG METABOLISM AND DISPOSITION (2017)
Quantification of piroxicam and 5′-hydroxypiroxicam in human plasma and saliva using liquid chromatography-tandem mass spectrometry following oral administration
Adriana Maria Calvo et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2016)
PBPK modeling and simulation in drug research and development
Xiaomei Zhuang et al.
ACTA PHARMACEUTICA SINICA B (2016)
Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects
Yun-Jeong Lee et al.
ARCHIVES OF PHARMACAL RESEARCH (2015)
Physiologically Based and Population PK Modeling in Optimizing Drug Development: A Predict-Learn-Confirm Analysis
A. Suri et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers
Dolores Ochoa et al.
PHARMACOGENOMICS (2015)
Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro
Li Wang et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2015)
Piroxicam Immediate Release Formulations: A Fasting Randomized Open-Label Crossover Bioequivalence Study in Healthy Volunteers
Sally A. Helmy et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2014)
CYP2C9*3 and *13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects
Chang-Ik Choi et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Effects of CYP2C9☆1/☆3 and ☆1/☆13 on the pharmacokinetics of losartan and its active metabolite E-3174
Jung-Woo Bae et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2012)
Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: Extension to describe performance of solid dosage forms
Kirstin Thelen et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics
Jung-woo Bae et al.
ACTA PHARMACOLOGICA SINICA (2011)
Effects of the CYP2C9*1/*13 Genotype on the Pharmacokinetics of Lornoxicam
Chang-Ik Choi et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2011)
Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam
Jung-Woo Bae et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Evolution of a Detailed Physiological Model to Simulate the Gastrointestinal Transit and Absorption Process in Humans, Part 1: Oral Solutions
Kirstin Thelen et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Relative Bioavailability of Two Oral Formulations of Piroxicam 20 mg: A Single-Dose, Randomized-Sequence, Open-Label, Two-Period Crossover Comparison in Healthy Mexican Adult Volunteers
Jose Antonio Palma-Aguirre et al.
CLINICAL THERAPEUTICS (2010)
Physiologically Motivated Time-Delay Model to Account for Mechanisms Underlying Enterohepatic Circulation of Piroxicam in Human Beings
Martina Tvrdonova et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2009)
General approach for the calculation of tissue to plasma partition coefficients
Walter Schmitt
TOXICOLOGY IN VITRO (2008)
Impact of CYP2C9*3/*3 genotype on the pharmacokinetics and pharmacodynamics of piroxicam
Jamila A. Perini et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes
Masuhiro Nishimura et al.
DRUG METABOLISM AND PHARMACOKINETICS (2006)
Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam
JA Perini et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm
K Ito et al.
DRUG METABOLISM AND DISPOSITION (2005)
A pharmacokinetic study of piroxicam in children
P Dix et al.
ANAESTHESIA (2004)
Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: Effect on atypical, kinetic metabolism profiles
TS Tracy et al.
DRUG METABOLISM AND DISPOSITION (2002)
In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P4502C9:: correlation with CYP2C9 genotype and in-vivo pharmacokinetics
CY Tang et al.
PHARMACOGENETICS (2001)
Share Paper
